Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Management of Myopic Choroidal Neovascularization

by Professor Dr. Frank G. Holz

Professor Dr. Frank G. Holz provides his perspective on the management of myopic choroidal neovascularization (myopic CNV), focusing on his clinical experiences treating patients with Lucentis® (ranibizumab) in his clinic within the Department of Ophthalmology at the University of Bonn in Germany.

(0:10) What is myopic CNV? And, how is it diagnosed?

(1:13) How important is early diagnosis and treatment for myopic CNV?

(1:52) What is the standard of care in treating myopic CNV?

(3:21) How effective is Lucentis in treating myopic CNV?

(3:55) How has the impact of having Lucentis for treating myopic CNV affected your retina service in terms of capacity and any other impact?

(4:45) How does your usage of Lucentis differ when treating myopic CNV vs. wAMD

(5:34) When you treat with Lucentis, how do you approach each patient in terms of dosing and monitoring?

(6:54) In the RADIANCE subgroup analysis, what differences were noted between East Asian and Caucasian patients?

The answers provided are based on the physician’s own experiences of anti-VEGF treatments in Germany. Labels may vary in other countries and the discussion may not reflect local practice or may not be representative for all patients.

* This video is intended for physicians outside the U.S.

8,118 video views since .
9,924 total series views.

Novartis Lucentis

Novartis Pharma AG

CH-4002 Basel, Switzerland                               ©2014 Novartis Pharma AG                             Dec 2014                        GLO/LUC/0066k